Check-Cap Ltd. (MBAI)vsWaters Corporation (WAT)
MBAI
Check-Cap Ltd.
$1.53
-8.38%
HEALTHCARE · Cap: $10.67M
WAT
Waters Corporation
$365.36
-2.95%
HEALTHCARE · Cap: $34.91B
Smart Verdict
WallStSmart Research — data-driven comparison
WAT leads profitability with a 11.9% profit margin vs 0.0%. MBAI trades at a lower P/E of 2.1x. WAT earns a higher WallStSmart Score of 50/100 (C-).
MBAI
Avoid28
out of 100
Grade: F
WAT
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MBAI.
Margin of Safety
-84.6%
Fair Value
$178.29
Current Price
$365.36
$187.07 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 120 in profit
Conservative balance sheet, low leverage
Revenue surging 91.4% year-over-year
Safe zone — low bankruptcy risk
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Trading at 8.5x book value
ROE of 2.9% — below average capital efficiency
Operating margin of 2.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : MBAI
The strongest argument for MBAI centers on P/E Ratio, Return on Equity, Debt/Equity.
Bull Case : WAT
The strongest argument for WAT centers on Revenue Growth, Altman Z-Score. Revenue growth of 91.4% demonstrates continued momentum.
Bear Case : MBAI
The primary concerns for MBAI are Revenue Growth, EPS Growth, Market Cap.
Bear Case : WAT
The primary concerns for WAT are PEG Ratio, Price/Book, Return on Equity. A P/E of 45.2x leaves little room for execution misses.
Key Dynamics to Monitor
MBAI profiles as a value stock while WAT is a growth play — different risk/reward profiles.
WAT carries more volatility with a beta of 1.20 — expect wider price swings.
WAT is growing revenue faster at 91.4% — sustainability is the question.
MBAI generates stronger free cash flow (-46,000), providing more financial flexibility.
Bottom Line
WAT scores higher overall (50/100 vs 28/100) and 91.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Check-Cap Ltd.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology products. The company is headquartered in Isfiya, Israel.
Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?